SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Indications -- Psoriasis/Chronic Inflammation
An SI Board Since February 2001
Posts SubjectMarks Bans
631 42 0
Emcee:  scaram(o)uche Type:  Moderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
381NF-kappaB / RNA panning 3/19/2003-- Using a new approach, Mayo Clinic researchenigel bates-3/20/2003
380Angiotech announces positive Phase 1 Psoriasis results Wednesday March 19, 9:01 keokalani'nui-3/19/2003
379Molecular Events At Root of Common Arthritis 3/14/2003 -- Scientists have discnigel bates-3/17/2003
378>> Any thoughts << Well, we don't want too much chat in the thrscaram(o)uche-3/10/2003
377This sounds pretty good to me, but I don't know much. Any thoughts? --------fred hayes-3/10/2003
376>> Genentech Announces March 21 Webcast Discussion of Data Presented at thIcebrg-3/7/2003
375Genentech Announces March 21 Webcast Discussion of Data Presented at the Americascaram(o)uche-3/7/2003
374[ IL-12 receptor beta1 deficient patients, re. CATG ] Eur J Immunol 2003 Jan;33scaram(o)uche-3/5/2003
373U.S. panel wants more data on arthritis drug risk Tuesday March 4, 6:45 pm ET Bkeokalani'nui-3/4/2003
372>> Moreover, the medication has the potential to cause cancer, a risk thatscaram(o)uche-3/4/2003
371Psoriasis Relief, at A Price New Drug Has High Cost, Possible Risks By Jennifer Icebrg-3/4/2003
370HUMIRA(TM) (adalimumab) in psoriasis and psoriatic arthritis... ABBOTT PARK, Ilnigel bates-3/3/2003
369Is there a "bad moon" rising for these companies.... cbs.marketwatch.cArthur Radley-3/1/2003
368quatrx.com QUATRX PHARMACEUTICALS INITIATES PHASE II STUDY OF LEAD COMPOUND IN software salesperson-3/1/2003
367[ Raptiva BLA accepted, Genentech/XOMA ] XOMA Announces Notification of FDA Accscaram(o)uche-2/28/2003
366Guess we all saw this coming.. they had no other option.. BTRN files Chapter II.Arthur Radley-2/27/2003
365thanks! (eom)scaram(o)uche-2/26/2003
364Morphosys is to issue 588,160 shares to CAT and 363,466 to XOMA this quarter. Tkeokalani'nui-2/26/2003
36312.5%. I'll try to locate the source and confirm.keokalani'nui-2/26/2003
362CEO of CAT mentioned the fraction in a recent presentation. Maybe H&Q? I tscaram(o)uche-2/26/2003
361<i>CAT owns what percentage of MorphoSys? </i> Message 18365099 So, nigel bates-2/26/2003
360Serono Submits Application for European Union Approval of Raptiva(TM) for Psoriascaram(o)uche-2/26/2003
359>> The Chugai news follows separate trials that indicate cancer drug MabThIcebrg-2/25/2003
358>> Roche / Chugai / MRA << Message 18169168scaram(o)uche-2/25/2003
357One reason I like the OGSI deal. CAT owns what percentage of MorphoSys?scaram(o)uche-2/25/2003
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News